NantHealth, Inc. and NantOmics, LLC announced joint results that show significant improvements in the accuracy of diagnosis when combining tumor-normal DNA analysis with tumor RNA analysis — as well as the risk for a higher error rate in tumor-only sequencing. The research is included in a paper, Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget is a multidisciplinary traditional journal focused on making scientific results rapidly and widely available so that exceptional discoveries can be shared quickly. The published results of the NantOmics and NantHealth study show the precision derived from GPS Cancer’s comprehensive approach that combines tumor and normal DNA sequencing with RNA sequencing. Highlights from the study include: 95% of genomic variants identified from tumor-only sequencing originated in the germline, therefore, these variants were single nucleotide polymorphisms (SNPs) and false positive tumor somatic variants. After filtering based on population allele frequency to remove SNPs, the false positive rate remained as high as 48%. 29% of lung cancer patients had a false positive variant call in at least one of 12 genes with directly targetable drugs. 18% of true somatic variants identified from tumor and normal DNA sequencing were not expressed in RNA, showing the importance of RNA sequencing to verify gene and variant expression. clinical setting, it is important to sequence the tumor and normal DNA as well as the tumor RNA as treatment decisions based on tumor-only sequencing may result in ineffective therapies while also increasing the risk of negative drug-related side effects. GPS Cancer provides a precise and comprehensive molecular profile, integrating tumor-normal sequencing of DNA with RNA sequencing. This approach overcomes the challenges faced by tumor-only DNA sequencing, equipping oncologists with insights that they can rely on to inform their personalized treatment strategies.